AbbVie buys cancer drugmaker

Article Excerpt

ABBVIE INC. $152 is a buy. The company (New York symbol ABBV; High-Growth Dividend Payer Portfolio, Manufacturing sector; Shares outstanding: 1.8 billion; Market cap: $273.6 billion; Dividend yield: 4.1%; Dividend Sustainability Rating: Above Average; www.abbvie.com) makes biopharmaceuticals, with leading positions in immunology, oncology, aesthetics, neuroscience and eye care. With the February 2024, AbbVie will raise your quarterly dividend by 4.7%, to $1.55 a share from $1.48. The new annual rate of $6.20 a share yields 4.1%. The company has agreed to acquire ImmunoGen Inc. (Nasdaq symbol IMGN) for $10.1 billion. That firm’s main product is Elahere, an ovarian cancer therapy. The purchase will help AbbVie replace revenue from Humira, its arthritis drug that recently lost its patent protection. ImmunoGen will add to overall earnings in 2027. AbbVie is buy. buy…